Effects of Spironolactone and Chlorthalidone on Cardiovascular Structure and Function in Chronic Kidney Disease

Autor: Vanessa Melville, Nicola C. Edwards, Richard P. Steeds, Thomas F. Hiemstra, Anna S Herrey, Samir Mehta, Iain M. MacIntyre, Jonathan N. Townend, Amreen Kaur, Anna M Price, Tariq E. Farrah, Peter J. Greasley, Natalie Ives, Ian B. Wilkinson, David C. Wheeler, Rebekah Wale, Charles J. Ferro, Neeraj Dhaun, David J. Webb, Gemma Slinn

Publikováno v: Edwards, N C, Price, A M, Mehta, S, Hiemstra, T F, Kaur, A, Greasley, P J, Webb, D J, Dhaun, N, MacIntyre, I M, Farrah, T, Melville, V, Herrey, A, Slinn, G, Wale, R, Ives, N, Wheeler, D C, Wilkinson, I, Steeds, R P, Ferro, C J & Townend, J N 2021, ' Effects of Spironolactone and Chlorthalidone on Cardiovascular Structure and Function in Chronic Kidney Disease : A Randomized, Open-Label Trial ', Clinical Journal of the American Society of Nephrology . https://doi.org/10.2215/CJN.01930221
Clin J Am Soc Nephrol

Background and objectives In a randomized double-blind, placebo-controlled trial, treatment with spironolactone in early-stage CKD reduced left ventricular mass and arterial stiffness compared with placebo. It is not known if these effects were due t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b01a2960a7505daca1d3d942dbd8ab0f
https://doi.org/10.2215/cjn.01930221